On the implementation of regional programs of subsidized drug provision in the subjects of the Russian Federation

Introduction. The regional programs of the subsidized provision of medicines (RPSPM) implemented in the subjects of the Russian Federation are an important state instrument in the field of medicine provision of citizens. 

Purpose. To study the features of the implementation of RPSPM in various subjects of the Russian Federation over 2018–2019.

Material and methods. During the study, the data provided by the health authorities and the pharmaceutical service of 21 constituent entities of the Russian Federation were processed.

Results. The median of funding in the studied subjects of the Russian Federation amounted to 713.1 million rubles in 2018 and 753.1 million rubles in 2019. The average actual costs per one applied beneficiary (± standard error) was 2685 ± 941 rubles in 2018 and 2404 ± 780 rubles in 2019. At the end of 2018, about 22.7 million prescriptions were established to be written out in the analyzed subjects of the Russian Federation within the framework of the RPPPM, at the end of 2019 — about 26.2 million prescriptions. The median cost of one prescription reached 1,327 rubles in 2018 and 2,162 rubles in 2019. Comparative analysis showed that the indicators of the funding volume for the RPSPM per beneficiary per year in different subjects of the Russian Federation differ significantly, the median (interquartile range) in 2018 was 6,704 rubles (3,436–11,576 rubles), in 2019 — 8,166 rubles (4,162–10,211 rubles).

Limitations. Taking into account the administrative-territorial division of the Russian Federation, in the study we analyzed data on the implementation of the RPSPM for about 25% of the constituent entities of the Russian Federation with various infrastructural, socio-economic, demographic indicators, which is a fairly reference sample group.

Conclusion. Thus, we studied the indicators of the implementation of the RPSPM in 21 subjects of the Russian Federation. During 2018–2019 in the analyzed subjects of the Russian Federation, regional beneficiaries had different opportunities to receive medicine assistance within the framework of the RPSPM.

Contribution of the authors:

Petrukhina I.K. — research concept and design, editing.

Yagudina R.I. — research concept and design, editing.

Ryazanova T.K. — statistical processing, writing the text, compilation of the list of literature.

Kurkin V.A. — research concept and design.

Egorova A.V. — material collection and processing.

Loginova L.V. — material collection and processing.

Khusainova A.I. — material collection and processing.

Blinkova P.R. — material collection and processing.

All authors are responsible for the integrity of all parts of the manuscript and approval of the manuscript final version.

Acknowledgment. The study had no sponsorship. We thank the healthcare and pharmaceutical service management bodies of the 21 analyzed subjects of the Russian Federation for the statistical data provided.

Conflict of interest. The authors declare no conflict of interest.

Received: August 03, 2020

Accepted: November 17, 2020

Published: May 04, 2022

1. Telnova E.A., Proklova T.N. The program continues to work, and the problems remain. Byulleten’ natsional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya imeni N.A. Semashko. 2019; (2): 99–112. https://doi.org/10.25742/NRIPH.2019.02.013 (in Russian)

2. Petrukhina I.K., Yagudina R.I., Egorova A.V., Ryazanova T.K. Implementation of the federal drug assistance program in the Privolzhsky federal district, analysis of indicators. Aspirantskiy vestnik Povolzh’ya. 2018; (1–2): 25–32. https://doi.org/10.17816/2075-2354.2018.18.25-32 (in Russian)

3. Sirotko M.L. Evaluation and characteristics of population ageing. Nauka i innovatsii v meditsine. 2018; (4): 68–72. (in Russian)

4. Telnova E.A., Zagorudchenko A.A. About the state of preferred medicinal provision. Byulleten’ natsional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya im. N.A. Semashko. 2021; (2): 72–81. https://doi.org/10.25742/NRIPH.2021.02.009 (in Russian)

5. Telnova E.A. The analysis and assessment of problems of medicinal support in the Russian Federation in actual conditions. Problemy sotsial’noy gigieny, zdravookhraneniya i istorii meditsiny. 2021; 29(3): 415–20. https://doi.org/10.32687/0869-866X-2021-29-3-415-420 (in Russian)

6. Orlov A.S. Analysis of major trends and price changes in the segment of preferential drug provision of Russian pharmaceutical market. Ekonomika i upravlenie: nauchno-prakticheskiy zhurnal. 2015; (5): 4–13. (in Russian)

7. DSM Group. Analytical review «Russian pharmaceutical market. Results of 2018». Available at: https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdf (in Russian)

8. Sura M.V. Provision of medicines for outpatient treatment financed from the regional budgets in the framework of regional programs of state guarantees of free medical care. Meditsinskie tekhnologii. Otsenka i vybor. 2017; 3(29): 41–52. (in Russian)

9. Petrukhina I.K., Kurkin V.A. Analysis of the implementation of the programmes medical drug provision of persons with benefits in regions. Sibirskiy meditsinskiy zhurnal (Irkutsk). 2015; 134(3): 81–4. (in Russian)

10. Segment of regional benefits. Remedium. 2019; (S13): 99–104. (in Russian)

11. DSM Group. Analytical review «Russian pharmaceutical market. Results of 2019». Available at: https://www.dsm.ru/docs/analytics/Annual_report_2019_DSM_web.pdf (in Russian)

12. Pilshchikova V.V., Shil’tsova T.A., Vasil’ev Yu.A. Analysis of the strategy of drug provision of certain categories of the population of the Krasnodar region. Novye tekhnologii. 2021; 17(4): 94–102. https://doi.org/10.47370/2072-0920-2021-17-4-94-102 (in Russian)

13. Samoylova A.V., Vovk E.G., Yagudina R.I., Serpik V.G. Comparative analysis of the number of citizens in the system of preferential drug provision: quantitative characteristics. Vestnik Roszdravnadzora. 2021; (6): 56–62. (in Russian)

14. Aleksandrova O.Yu., Nagibin O.A., Burtseva M.N. Implementing the program for essential pharmaceutical provision (ONLP) – challenges faced by regions. Remedium. 2015; (12): 62–5. (in Russian)

15. Luk”yantseva D.V., Mel’nikova L.S., Tatarinov A.P. The international practice of drug supply in the outpatient segment. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2017; 10(4): 44–52. https://doi.org/10.17749/2070-4909.2017.10.4.044-052 (in Russian)